Search

Your search keyword '"Ewer A"' showing total 3,876 results

Search Constraints

Start Over You searched for: Author "Ewer A" Remove constraint Author: "Ewer A"
3,876 results on '"Ewer A"'

Search Results

1. VersaPRM: Multi-Domain Process Reward Model via Synthetic Reasoning Data

2. ENTP: Encoder-only Next Token Prediction

3. Zum Referentenentwurf des Bundesministeriums für Wohnen, Stadtentwicklung und Bauwesen eines Gesetzes zur Stärkung der integrierten Stadtentwicklung (Stand 29.7.2024) – Bearbeitungsstand: August 2024: Stellungnahme des Deutschen Anwaltvereins vorbereitet durch die Ausschüsse Verwaltungsrecht und Umweltrecht

4. High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.

5. The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E

6. Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines

8. A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults

9. Necrotizing enterocolitis: current perspectives

10. A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against Mycobacterium avium complex subspecies in patients with active Crohn’s diseaseResearch in context

11. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial

12. Monitoring of indoor air quality at a large sailing cruise ship to assess ventilation performance and disease transmission risk

14. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.

17. Cerclage suture type to prevent pregnancy loss in women requiring a vaginal cervical cerclage: the C-STICH RCT

22. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study

23. CULTURA PEDAGÓGICA Y COMPETENCIAS DEL DOCENTE UNIVERSITARIO DESDE LA PERCEPCIÓN DEL ESTUDIANTE

25. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

32. Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

33. Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination

34. Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya [version 1; peer review: 2 approved]

38. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

39. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry

40. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

41. Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial

44. Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

45. Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.

46. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis

47. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis

48. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas

49. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

Catalog

Books, media, physical & digital resources